Core Points - CoreWeave, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934 during the class period from March 28, 2025, to December 15, 2025 [1] - The lawsuit claims that CoreWeave and its executives made misleading statements regarding the company's ability to meet customer demand and the risks associated with reliance on a single third-party data center supplier [1] - Significant events leading to the lawsuit include a failed merger with Core Scientific, which caused a share price drop of over 6%, and a subsequent revenue guidance reduction that led to a further decline of more than 16% in share price [1] Company Overview - CoreWeave is positioned as an AI cloud computing company and had announced a deal worth up to $11.9 billion with OpenAI shortly before its IPO [1] - The company also attempted to acquire Core Scientific, a major player in digital infrastructure for high-performance computing, in an all-stock transaction [1] Allegations and Impact - The lawsuit alleges that CoreWeave overstated its service capabilities and downplayed the risks associated with its data center supplier, which were likely to negatively impact revenue [1] - On October 30, 2025, Core Scientific announced it did not have enough shareholder votes to approve the merger with CoreWeave, leading to a significant drop in CoreWeave's stock price [1] - Following a revenue guidance cut on November 10, 2025, due to delays from a third-party data center developer, CoreWeave's CEO acknowledged that multiple data centers were affected, resulting in a further stock price decline [1] - A December 15, 2025, article from The Wall Street Journal revealed more severe data center delivery issues than previously disclosed, causing an additional 3.4% drop in share price [1]

Core Viewpoint - Faruqi & Faruqi, LLP is reminding investors of F5, Inc. about the deadline for a securities class action lawsuit, which is set for February 17, 2026, due to allegations of misleading statements related to a significant security breach affecting the company's capabilities [1] Group 1: Company Overview - F5, Inc. (NASDAQ: FFIV) is facing a federal securities class action lawsuit alleging violations of federal securities laws by making false or misleading statements regarding its security capabilities [1] - The lawsuit claims that F5 was experiencing a significant security breach that impacted its ability to secure client data, which was not disclosed to investors [1] Group 2: Financial Impact - On October 27, 2025, F5 reported fourth quarter fiscal year 2025 results that fell significantly below market growth expectations for fiscal 2026, largely attributed to the security breach [1] - Following the announcement, F5's stock price dropped from $290.41 per share on October 27, 2025, to $258.76 per share by October 29, 2025, marking a decline of 10.9% in just two days [1] Group 3: Legal Proceedings - The deadline for investors to seek the role of lead plaintiff in the class action lawsuit is February 17, 2026, and any member of the class can move the court to serve as lead plaintiff [1] - Faruqi & Faruqi encourages individuals with information regarding F5's conduct, including whistleblowers and former employees, to come forward [1]

Core Viewpoint - A class action lawsuit has been filed against REGENXBIO, Inc. for allegedly misleading investors about the viability of its drug candidate RGX-111, which has faced significant safety concerns and regulatory scrutiny [1]. Group 1: Allegations and Legal Proceedings - The lawsuit claims that REGENXBIO misrepresented the safety and efficacy of RGX-111, a gene therapy for MPS I, despite knowing about serious safety issues, including the potential for CNS neoplasm [1]. - The FDA placed a clinical hold on RGX-111 after a participant developed an intraventricular CNS tumor during the Phase I trial, leading to a significant drop in the company's stock price from $13.41 to $11.01, a decline of 17.8% in one day [1]. - Shareholders are encouraged to participate in the class action, with a deadline for lead plaintiff submissions set for April 14, 2026 [1]. Group 2: Company Background - REGENXBIO, Inc. is a clinical-stage biotechnology company focused on gene therapies that deliver functional genes to cells with genetic defects in the United States [1].

In addition, the company announced it will delay the filing of its Form 10-Q for the quarter ended December 31, 2025 and that, when filed, it expects it will "report material weaknesses in the company's internal control over financial reporting†for the period covered in the report, as well as the full fiscal year ended March 31, 2025, and the first two quarters of fiscal year 2026. Additionally, the company revealed that its Chief Financial Officer, David Wysher, and General Counsel, Edward Sebold, have bot ...

Core Viewpoint - Hub Group, Inc. announced a significant accounting error leading to a 20% drop in its share price, with potential implications for its financial statements and investor trust [1][3]. Financial Impact - The accounting error resulted in a $77 million understatement of purchased transportation costs and accounts payable for the first three quarters of 2025 [2]. - Hub Group plans to restate its financial statements for the first three quarters of 2025 and is assessing the impact on its consolidated financial statements for the years ended December 31, 2024, and 2023 [3]. Market Reaction - Following the announcement of the accounting error, Hub Group's shares fell over 20% on February 5, 2026, and continued to decline the next day, indicating significant investor concern [1][3].

Core Viewpoint - The complaint against F5 alleges violations of federal securities laws due to false or misleading statements regarding its security capabilities, particularly in light of a significant security breach affecting its key offerings [2] Group 1: Allegations and Legal Proceedings - The complaint claims that F5 and its executives failed to disclose the true state of the company's security capabilities, which were compromised by a significant security breach [2] - The breach is said to have a substantial impact on F5's ability to capitalize on the security market [2] - A court-appointed lead plaintiff has been designated, representing the largest financial interest in the relief sought by the class [3] Group 2: Call for Information - The law firm Faruqi & Faruqi encourages individuals with information regarding F5's conduct to come forward, including whistleblowers and former employees [4]

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc, alleging that the company misled investors regarding the results of its Phase 3 studies for the drug setrusumab, which is intended for treating Osteogenesis Imperfecta [1][2]. Group 1: Allegations and Misleading Information - The lawsuit claims that Mereo BioPharma provided investors with overly optimistic statements about the expected outcomes of the Phase 3 ORBIT and COSMIC studies, asserting confidence in setrusumab's ability to reduce annualized fracture rates [2]. - It is alleged that while making these positive statements, Mereo concealed material adverse facts about the studies, which ultimately did not meet their primary endpoints of reducing annualized clinical fracture rates compared to placebo or bisphosphonate control groups [2][3]. Group 2: Impact on Stock Price - Following the announcement on December 29, 2025, that neither the ORBIT nor COSMIC studies met their primary endpoints, Mereo's American Depository Shares (ADS) plummeted from $2.31 per share to $0.29 per share, marking a decline of over 87.7% [3]. Group 3: Class Action Participation - Shareholders of Mereo BioPharma may be eligible to participate in the class action lawsuit, with options to serve as lead plaintiff or remain an absent class member [4].

NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds agilon health, inc. (“agilon” or the “Company”) (NYSE:AGL) investors of the March 2, 2026 lead plaintiff deadline to seek lead plaintiff appointment in the class action filed on behalf of investors who acquired agilon securities between February 26, 2025 through August 4, 2025 (“the Class Period”). Courts do not consider applications filed after the lead plaintiff deadline. The lead plaintiff oversees the litigation on b ...

NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds F5, Inc. (“F5” or the “Company”) (NASDAQ:FFIV) investors of the February 17, 2026 lead plaintiff deadline to seek lead plaintiff appointment in the class action filed on behalf of investors who acquired F5 securities between October 28, 2024 through October 27, 2025 (“the Class Period”). Courts do not consider applications filed after the lead plaintiff deadline. The lead plaintiff oversees the litigation on behalf of th ...

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a class action was filed on behalf of all investors who purchased or otherwise acquired Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1, 2024 and December 16, 2025. Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. All representation is on a contingency fee basis. Shareholders pay no fees o ...